Testing Eplerenone with Statins to Reduce Artery Inflammation in People with HIV
Tests eplerenone added to statins to reduce artery inflammation in adults with HIV.
Plain-language title generated from the registry record
Registry title: Reducing Arterial Inflammation Using Eplerenone and Statins in HIV
Key facts
- Where
- Boston and Los Angeles, United StatesSee the 2 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Source: NCT07892664, who can take part
Where in United States
- Massachusetts General HospitalBoston, United StatesNo longer taking part
- UCLA Center for Clinical AIDS Research and Education (CARE)Los Angeles, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Massachusetts General Hospital
- Trial code
- NCT07892664
- Record updated
- 23 October 2026
- Original description
HIV has transitioned to a chronic disease in which well-treated persons remain at higher risk for heart disease when compared to the general population. Statin medications have been shown to reduce the number of events related to heart disease, but there are still individuals who will have complications from heart disease despite statin use. This study is being conducted to determine whether adding on another medication to statins called eplerenone, which has been shown to reduce inflammation in the heart vasculature among persons with HIV, can further decrease the risk of heart disease in HIV through its anti-inflammatory and blood pressure-lowering potential.Read full original descriptionShow less
Study to Understand the Reduction in Arterial Inflammation Combining Statins and Eplerenone
HIV has transitioned to a chronic disease in which well-treated persons remain at higher risk for heart disease when compared to the general population. Statin medications have been shown to reduce the number of events related to heart disease, but there are still individuals who will have complications from heart disease despite statin use. This study is being conducted to determine whether adding on another medication to statins called eplerenone, which has been shown to reduce inflammation in the heart vasculature among persons with HIV, can further decrease the risk of heart disease in HIV through its anti-inflammatory and blood pressure-lowering potential.
Inclusion: ART use >12 months; Viral load <200 copies/mL; Stable use (>90 days) of moderate-intensity statin (pitavastatin 4mg daily, atorvastatin 10-20mg daily, rosuvastatin 5-10mg daily; simvastatin 20-40mg; pravastatin 40-80mg) or maximally tolerated statin if prior history of statin intolerance; ASCVD risk ≥5%; Baseline TBR≥2.3 on cardiac 18F-FDG-PET.
Exclusion: Use of ritonavir, nelfinavir, clarithromycin, and other strong inhibitors of CYP3A4 and CYP3A4 inducers (boosting doses of ritonavir 100mg are allowed); Steroids or other anti-inflammatory agents within last 1 month; NSAIDs are allowed; Significant radiation exposure from clinical or research scans, cumulative exposure ≥25mSv over 12 months is not allowed; Known Addison's disease; Active infection (besides HIV); Iodine contrast allergy; Use of potassium (K) supplements; Use of potassium-sparing diuretic; Type 1 DM or poorly controlled type 2 DM with HbA1c>7.5%; Creatinine (Cr)>1.5 mg/dL or eGFR<60mL/min/1.73m²; Hemoglobin<10.0 g/dL; MRA use within the last 90 days; Known HFrEF or primary aldosteronism; Newly initiated GLP1-RA or anti-hypertensive within 90 days, stable use >90 days is allowed; SBP<90mmHg; K>5.5 mEq/L; Pregnant, seeking pregnancy, breastfeeding; Known severe coronary artery stenosis, defined as ≥50% stenosis in the left main coronary artery or >70% stenosis.